文献速递白血病

坦桑尼亚慢性髓性白血病患者伊马替尼分子学应答研究

Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania.
PubMed 文献 · Blood Adv · 2021-01-01

仅37例(23.4%)达到最佳分子学应答;诊断前需红细胞输注和因血细胞减少需中断药物是治疗失败的独立预测因素;22个月随访时无应答组生存率最低(78.6%),最佳应答组最高(97.0%)。

要点

  • 坦桑尼亚CML患者伊马替尼治疗后仅23.4%达到最佳分子学应答。
  • 诊断前需红细胞输注(AOR 3.4)和因血细胞减少中断药物(AOR 2.26)预测治疗失败。
  • 22个月随访无应答组生存率78.6%,最佳应答组97.0%。

核心结论

  • 坦桑尼亚大多数接受伊马替尼治疗的CML患者未获得深度分子学应答。
  • 治疗失败可归因于晚期诊断、需多次中断药物的血细胞减少及治疗依从性差。

研究设计与样本

  • 采集EDTA抗凝血,用Gene Xpert系统检测BCR/ABL比值判定分子学应答。
  • 采用多因素多项式逻辑回归分析治疗失败的预测因素。

主要发现

  • 158例成人患者中位年龄45岁(范围18-86岁)。
  • 仅37例(23.4%)达到最佳分子学应答。
  • 诊断前需红细胞输注者治疗失败风险升高(AOR 3.4;95% CI 1.32-9.17)。
  • 因血细胞减少需中断药物者治疗失败风险升高(AOR 2.26;95% CI 1.03-4.96)。
  • 22个月随访生存率:治疗失败组78.6%(95% CI 69.4-85.4),最佳应答组97.0%(95% CI 80.9-99.6)。

临床怎么用

  • 在资源有限地区应常规开展分子学监测以及时发现治疗失败。
  • 对诊断前需输血或治疗中出现血细胞减少需中断药物者应加强监测和干预。

局限性

  • 单中心研究,样本量158例。
  • 随访时间22个月,未报告更长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imatinib is the mainstay of treatment of patients with chronic myeloid leukemia (CML) in Tanzania. Monitoring molecular response to therapy by real-time polymerase chain reaction at defined milestones is necessary for early detection of treatment failure. However, this assay is not routinely performed in Tanzania; therefore, the depth of molecular response among patients with CML is not known. A total of 158 patients with previously diagnosed CML who received imatinib treatment were recruited from January 2019 and followed up through October 2020 at Ocean Road Cancer Institute. Information was obtained at the time of diagnosis and follow-up. Blood samples were collected in EDTA tubes to measure the BCR/ABL ratio on the Gene Xpert system for molecular response determination. The median age of the 158 adult patients was 45 years (range, 18-86). By reference to established treatment milestones, only 37 (23.4%) achieved optimal molecular response. Signs of advanced-stage disease, in particular the need for red cell transfusions before diagnosis (adjusted odds ratio [AOR], 3.4; 95% CI, 1.32-9.17) and cytopenias (AOR, 2.26; 95% CI, 1.03-4.96) necessitating drug interruptions were statistically validated predictors of treatment failure on multivariate, multinomial logistic regression. Patient survival at the 22-month follow-up was lowest, with 78.6% (95% CI, 69.4-85.4) in the failure-to-respond category and highest in patients achieving optimal response 97.0% (95% CI, 80.9-99.6). In summary, the majority of patients with CML treated with imatinib in Tanzania do not obtain deep molecular response. This outcome can be attributed to late diagnosis, the development of cytopenias requiring multiple drug interruptions, and poor adherence to treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nasser A, Hussein A, Chamba C, et al. Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv. 2021. PMID: 33666650. doi:10.1182/bloodadvances.2020002973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。